Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 18, 2024
Context: This filing reports on the execution of a share repurchase programme initiated on November 11, 2024, under EU "Safe Harbour Rules." Novo Nordisk is a global healthcare company focused on diabetes and chronic diseases, employing approximately 72,000 people across 80 countries.
Key Financial Metrics and Share Repurchase Activity
Share Repurchase Programme Details:
- Overall Programme Cap: Up to DKK 20 billion over a 12-month period starting February 6, 2024.
- Current Sub-Programme (Nov 11, 2024 – Feb 3, 2025): Up to DKK 3,136,206,122.30.
- Transactions (Nov 11–15, 2024): 431,987 B shares repurchased for a total value of DKK 322,447,007.
- Average Purchase Price (Recent): Ranged between DKK 722.87 and DKK 765.36 per share.
Cumulative Repurchase Status (Since Feb 6, 2024):
- Total Shares Repurchased: 20,635,086 B shares.
- Total Value: DKK 17,186,240,885.
- Average Price: DKK 832.86 per B share.
Treasury Shares: Novo Nordisk holds 21,779,644 B shares as treasury shares, representing 0.5% of total share capital (4,465,000,000 total shares).
Other Financial Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change reported is the initiation of a new tranche of share buybacks on November 11, 2024, and the subsequent execution of transactions totaling DKK 322.4 million within five trading days. Additionally, 828 B shares were transferred due to incentive programmes, which were excluded from the Safe Harbour repurchase programme.
Guidance, Outlook, and Risks
Outlook: Management expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. As of the filing date, approximately DKK 2.8 billion of the total programme remains available.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the repurchase programme under EU regulations.
Key Facts for Investor Verification
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 2.8 billion remaining as of Nov 18, 2024).
- Confirm the impact of the 0.5% treasury share holding on earnings per share (EPS) calculations.
- Monitor the average repurchase price trend, noting the recent dip to DKK 722.87 compared to the cumulative average of DKK 832.86.
- Check subsequent filings for the final execution of the current sub-programme ending February 3, 2025.